Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Subscribe To Our Newsletter & Stay Updated